Elvitegravir for the treatment of HIV infection

Drugs of Today

Volumn 50, Issue 3, 2014, Pages 209-217

  Reviriego, Carlota ^a  

^a NONE

Author keywords

Cytochrome P450 3A4 inhibitors; Elvitegravir; GS 9137; HIV infection; HIV integrase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CYTOCHROME P450 3A; DARUNAVIR; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; INTEGRASE INHIBITOR; LOPINAVIR; MARAVIROC; PLACEBO; RALTEGRAVIR; RIFABUTIN; RITONAVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PHARMACOLOGY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSMENORRHEA; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE SPASM; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); RASH; SECONDARY METABOLISM; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIREMIA; WILD TYPE;

CYTOCHROME P450 3A4 INHIBITORS; ELVITEGRAVIR; GS-9137; HIV INFECTION; HIV INTEGRASE INHIBITORS;

ANIMALS; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; QUINOLONES; RITONAVIR;

EID: 84897378155     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.050.03.2122120     Document Type: Article

References (64)

1. Moore, R.D., Chaisson, R.E. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13(14): 1933-42 (Pubitemid 29509554)
2. Taylor, B.S., Wilkin, T.J., Shalev, N., Hammer, S.M. CROI 2013: Advances in antiretroviral therapy. Top Antivir Med 2013, 21(2): 75-89
3. Deeks, S.G., Lewin, S.R., Havlir, D.V. The end of AIDS: HIV infection as a chronic disease. Lancet 2013, 382(9903): 1525-33
4. Blanco, J.L., Varghese, V., Rhee, S.Y., Gatell, J.M., Shafer, R.W. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011, 203(9): 1204-14
5. Arribas, J.R., Eron, J. Advances in antiretroviral therapy. Curr Opin HIV AIDS 2013, 8(4): 341-9
6. Ramanathan, S., Mathias, A.A., German, P., Kearney, B.P. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011, 50(4): 229-44
7. Sharma, A.K., George, V., Valiathan, R., Pilakka-Kanthikeel, S., Pallikkuth, S. Inhibitors of HIV-1 entry and integration: recent developments and impact on treatment. Recent Pat Inflamm Allergy Drug Discov 2013, 7(2): 151-61
8. Schafer, J.J., Squires, K.E. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010, 44(1): 145-56
9. Molina, J.M., LaMarca, A., Andrade Villanueva, J. et al. Elvitegravir once-daily is non inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a phase 3 multicenter, randomized, double blind study. 6th IAS Conf HIV Pathog Treat Prev (July 17-20, Rome) 2011, Abst WELBB05
10. Correll, T., Klibanov, O.M. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 2008, 28(1): 90-101
11. FDA approves new combination pill for HIV treatment for some patients [news release]. U.S. Food and Drug Administration, August 27, 2012. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm317004.htm. Accessed March 17, 2014
12. Gilead receives complete response letters from U.S. Food and Drug Administration for elvitegravir and cobicistat [news release]. Gilead Sciences, April 29, 2013. http://www.gilead.com/news/press-releases/2013/4/gilead- receivescomplete-response-letters-from-us-food-and-drugadministration-for- elvitegravir-and-cobicistat. Accessed March 17, 2014
13. European Commission approves Gilead's Vitekta(TM), an integrase inhibitor for the treatment of HIV-1 infection [news release]. Gilead Sciences, November 18, 2013. http://www.gilead.com/news/press-releases/2013/11/european-commission- approves-gileads-vitekta-an-integrase-inhibitorfor-the-treatment-of-hiv1- infection. Accessed March 17, 2014
14. EPAR summary for the public. Vitekta, elvitegravir. EMA/593111/2013 European Medicines Agency, November 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Sumary-for-the-public/human/002577/WC500155578.pdf. Accessed March 17, 2014
15. DeJesus, E., Berger, D., Markowitz, M. et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006, 43(1): 1-5 (Pubitemid 44306480)
16. DeJesus, E., Berger, D., Markowitz, M. et al. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. 13th Conf Retroviruses Opportunistic Infect (CROI) (February 5- 9, Denver) 2006, Abst 160LB
17. Shimura, K., Kodama, E.N. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 2009, 20(2): 79-85
18. Ledford, R., Margot, N., Miller, M., McColl, D. Elvitegravir (GS-9137/JTK-303), an HIV-1 integrase inhibitor, has additive to synergistic interactions with other anti-retroviral drugs in vitro. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst MOPEA052
19. Matsuzaki, Y., Watanabe, W., Yamataka, K. et al. JTK- 303/GS 9137, a novel small-molecule inhibitor of HIV-1 integrase: Anti-HIV activity profile and pharmacokinetics in animals. 13th Conf Retroviruses Opportunistic Infect (CROI) (February 5-9, Denver) 2006, Abst 508
20. Stanfield-Oakley, S.A., Davison, D.K., Bowling, T.S., Greenberg, M.L. Synergistic in vitro antiretroviral activity of enfuvirtide and elvitegravir (GS-9137). 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 17-20, Chicago) 2007, Abst H-1051
21. Andreatta, K., Miller, M.D., White, K.L. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr 2013, 62(4): 367-74
22. Kawaguchi, I., Ishikawa, T., Ishibashi, M., Irie, S., Kakee, A. Safety and pharmacokinetics of single oral dose of JTK- 303/GS 9137, a novel HIV integrase inhibitor, in healthy volunteers. 13th Conf Retroviruses Opportunistic Infect (CROI) (February 5-9, Denver) 2006, Abst 580
23. Kearney. B.P., M., M., Zhong, L. et al. Pharmacokinetics/ pharmacodynamics of GS-9137 an HIV integrase inhibitor. 7th Int Workshop Clin Pharmacol HIV Ther (April 20-22, Lisbon) 2006, Abst 75
24. Molina, J.M., Lamarca, A., Andrade-Villanueva, J. et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012, 12(1): 27-35
25. Zolopa, A.R., Berger, D.S., Lampiris, H. et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, doseranging clinical trial. J Infect Dis 2010, 201(6): 814-22
26. Elion, R., Molina, J.M., Arribas Lopez, J.R. et al. Efficacy and safety results from a randomized, double blind, active controlled trial of elvitegravir (once-daily) versus raltegravir (twice-daily) in treatment-experienced HIV-positive patients: Long term 96-week data. 19th Int AIDS Conf (July 22-27, Washington, D.C.) 2012, Abst TUAB0105
27. Mathias, A.A., West, S., Hui, J., Kearney, B.P. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009, 85(1): 64-70
28. Collot-Teixeira, S., De Lorenzo, F., Waters, L. et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 2009, 85(4): 375-8
29. Elion, R., Gathe, J., Rashbaum, B. et al. The single tablet regimen of elvitegravir/cobicistat/emicitrabine/tenofovir disoproxil fumarate (QUAD) maintains a high rate of virologic suppression, and cobicistat is an effective pharmacoenhancer through 48 weeks. 50th Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 12-15, Boston) 2010, Abst H-938B
30. Zolopa, A., Ortiz, R., Sax, P. et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. 20th Conf Retroviruses Opportunistic Infect (CROI) (March 3-6, Atlanta) 2013, Abst 99LB
31. Cooper, D., Zolopa, A., Rockstroh, J. et al. Subgroup analyses of 96-week efficacy and safety of elvitegravir/cobicistat/ emtricitabine/tenofovir DF. IAS Conf HIV Pathog Treat Prev (June 30-July 3, Kuala Lumpur) 2013, Abst TUPE281
32. Crofoot, G., Ortiz, R., Mills, A., et al. Safety and tolerability of switching from twice daily raltegravir plus truvada to STRIBILD in virologically suppressed, HIV-1-infected subjects at week 24. IAS Conf HIV Pathog Treat Prev (June 30-July 3, Kuala Lumpur) 2013, Abst TUPE283
33. Mathias, A., Shen, G., Enejosa, J., Sekar, V., Mack, R., Tomaka, F., Kearney, B. Lack of pharmocokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/r. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst TUPDB03
34. Mathias, A., Hinkle, J., Enejosa, J., Piliero, P., Kearney, B. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and tipranavir/r. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst TUPDB06
35. Ramanathan, S., Mathias, A.A., Shen, G., Holmes, C., Kearney, B.P. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/ r. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst WEPEB014
36. Ramanathan, S., Kakuda, T.N., Mack, R., West, S., Kearney, B.P. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008, 13(8): 1011-7
37. Ramanathan, S., Skillington, J., Plummer, A., Hui, J., Shen, G., Cheng, A., Kearney, B.P. Lack of clinically relevant drugdrug interaction between ritonavir-boosted GS-9137 (GS- 9137/r) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF). 16th Int AIDS Conf (August 13-18, Toronto) 2006, Abst TUPE0080
38. Ramanathan, S., Lagan, K., Plummer, A., Hui, J., Shen, G., Cheng, A., Kearney, B.P. Lack of clinically relevant drug-drug interaction between the ritonavir-boosted HIV integrase inhibitor GS-9137/r and zidovudine (ZDV). 16th Int AIDS Conf (August 13-18, Toronto) 2006, Abst TUPE0088
39. Post, F., Villanueva, J.A., Fisher, M. et al. Renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and cobicistat-boosted protease inhibitor regimens in HIV-1- infected patients with mild to moderate renal impairment. IAS Conf HIV Pathog Treat Prev (June 30-July 3, Kuala Lumpur) 2013, Abst TUPE280
40. Mathias, A., Ramanathan, S., Hinkle, J. et al. Effect of atazanavir/r on the steady state pharmacokinetics of elvitegravir. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 17-20, Chicago) 2007, Abst A-1417
41. Mathias, A., Ramanathan, S., Hinkle, J. et al. A pharmacokinetic interaction between lopinavir/r and elvitegravir. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 17-20, Chicago) 2007, Abst A-1418
42. Ramanathan, S., Abel, S., Tweedy, S., West, S., Hui, J., Kearney, B.P. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr 2010, 53(2): 209-14
43. German, P., Warren, D., Wei, L. et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. 49th Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 12-15, San Francisco) 2009 Abst A1-1300
44. Bruce, R.D., Winkle, P., Custodio, J. et al. Pharmacokinetics of cobicistat-boosted elvitegravir administered in combination with methadone or buprenorphine/naloxone. 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 9-12, San Francisco) 2012, Abst A-1250
45. Ramanathan, S., Wang, H., Stondell, T. et al. Pharmaco - kinetics and drug interaction profile of cobicistat boosted- EVG with atazanavir, rosuvastatin or rifabutin. 13th Int Workshop Clinical Pharmacol HIV Ther (April 16-18, Barcelona) 2012, Abst O-03
46. Ramanathan, S., Shen, G., Hinkle, J. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents. 8th Int Workshop Clinical Pharmacol HIV Ther (April 16-18, Budapest) 2007, Abst 69
47. Garvey, E.P., Johns, B.A., Gartland, M.J. et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008, 52(3): 901-8 (Pubitemid 351358368)
48. Goethals, O., Clayton, R., Van Ginderen, M. et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008, 82(21): 10366-74 (Pubitemid 352691161)
49. McColl, D., Fransen, S., Gupta, S. et al. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase 2 study of elvitegravir (GS-9137). Antivir Ther 2007, 12(Suppl. 1): S11
50. Charpentier, C., Karmochkine, M., Laureillard, D. et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008, 9(9): 765-70
51. Garrido, C., Villacian, J., Zahonero, N. et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012, 56(6): 2873-8
52. Huang, W., Frantzell, A., Fransen, S., Petropoulos, C.J. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother 2013, 57(9): 4105-13
53. Abram, M.E., Hluhanich, R.M., Goodman, D.D. et al. Effect of primary elvitegravir resistance mutations in HIV-1 integrase on drug susceptibility and viral replicative fitness. Int HIV Hepat Virus Drug Resist Workshop Curativ Strategies (June 5-9, Sitges) 2012, Abst 3
54. Witmer, M., Danovich, R., Day, A., Ke, Y., Miller, M., Hazuda, D. Cross resistance between HIV-1 integrase strand transfer inhibitors (InSTIs) raltegravir, elvitegravir and second generation InSTIs. 48th Annu Intersci Conf Antimicrob Agents Chemother (ICAAC) Infect Dis Soc Am (IDSA) Annu Meet (October 25-28, Washington, D.C.) 2008, Abst H-1232
55. Bar-Magen, T., Sloan, R.D., Donahue, D.A. et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010, 84(18): 9210-6
56. Metifiot, M., Vandegraaff, N., Maddali, K. et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011, 25(9): 1175-8
57. Abram, M.E., Hluhanich, R.M., Goodman, D.D. et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013, 57(6): 2654-63
58. Shimura, K., Kodama, E., Sakagami, Y. et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK- 303/GS-9137). J Virol 2008, 82(2): 764-74
59. Gutierrez, C., Hernandez-Novoa, B., Perez-Elias, M.J. et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials 2013, 14(1): 10-6
60. Mphahlele, M., Hewer, R., Bronze, M. et al. Resistance associated imitations in HIV-1 subtype C primary viruses after in vitro passage with integrase inhibitors raltegravir, elvitegravir and dolutegravir. Int HIV Hepat Virus Drug Resist Workshop Curativ Strategies (June 4-8, Toronto) 2013, Abst 79
61. Roquebert, B., Damond, F., Collin, G. et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008, 62(5): 914-20
62. Xu, L., Anderson, J., Ferns, B. et al. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses 2008, 24(7): 1003-7
63. Charpentier, C., Roquebert, B., Delelis, O. et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother 2011, 55(3): 1293- 5
64. White, K.L., Kulkarni, R., Abram, M., Rhee, M., Fordyce, M., Miller, M.D. Primary and secondary analyses of emergent drug resistance through week 96 from the phase III studies of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Int HIV Hepat Virus Drug Resist Workshop Curativ Strategies (June 4-8, Toronto) 2013, Abst 80.